Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
Adi Diab(Cleveland Clinic), Brendan D. Curti(Providence Portland Medical Center), Fiore Cattaruzza(Sanofi (United States)), Andrew S. Brohl(Moffitt Cancer Center), Ute Hoch(University of Arizona), James Brugarolas(The University of Texas Southwestern Medical Center), Mehmet Asım Bilen(Emory Healthcare), Mario Q. Marcondes(Nektar Therapeutics (United States)), Brian L. Kotzin(Howard Hughes Medical Institute), Evidio Domingo‐Musibay(University of Minnesota), Erkut Borazanci(HonorHealth), Mary Tagliaferri(Nektar Therapeutics (United States)), Sandra P. D’Angelo(Memorial Sloan Kettering Cancer Center), Anthony P. Conley(The University of Texas MD Anderson Cancer Center), Jonathan Zalevsky(Nektar Therapeutics (United States)), Yunfeng Li(Jilin University), Shilpa Gupta(Cleveland Clinic)
Cited by 26
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
|Journal of Clinical Oncology|2015|1.1k
mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways
|Nature Medicine|2004|956
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869